Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis

The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) includes representatives from advocacy organizations, Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institute of Neurological Disorders and Stroke (NINDS), academic institutions, and industry partners along...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Multiple sclerosis Jg. 23; H. 5; S. 704 - 710
Hauptverfasser: Motl, Robert W, Cohen, Jeffrey A, Benedict, Ralph, Phillips, Glenn, LaRocca, Nicholas, Hudson, Lynn D, Rudick, Richard
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England 01.04.2017
Schlagworte:
Adult
Disability Evaluation
Exercise Test - methods
Female
Humans
Male
Middle Aged
Multiple Sclerosis - physiopathology
Multiple Sclerosis - rehabilitation
Outcome Assessment (Health Care)
Reproducibility of Results
Walking - physiology
validity
Ambulation
gait
multiple sclerosis
walking
reliability
ISSN:1477-0970
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) includes representatives from advocacy organizations, Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institute of Neurological Disorders and Stroke (NINDS), academic institutions, and industry partners along with persons living with multiple sclerosis (MS). One of the MSOAC goals is acceptance and qualification by regulators of performance outcomes that are highly reliable and valid, practical, cost-effective, and meaningful in MS. This article addresses the history, application, and psychometric properties of one such MSOAC metric of ambulation or walking namely, the timed 25-foot walk (T25FW). The T25FW has strong reliability over both brief and long periods of time in MS across a large range of disability levels. The outcome of walking speed from the T25FW has obvious real-world relevance and has correlated strongly with other measures of walking and lower extremity function. The T25FW is responsive for capturing intervention effects in pharmacological and rehabilitation trials and has an established value for capturing clinically meaningful change in ambulation. Directions for future research involve validating clinically meaningful improvements on the T25FW as well as determining whether 20% change is clinically meaningful across the disability spectrum. Researchers might further consider synchronizing accelerometers and motion sensors with the T25FW for capturing walking speed in everyday life and the patient's real environment.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1477-0970
DOI:10.1177/1352458517690823